vs
Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $7.2M, roughly 3.2× Arcturus Therapeutics Holdings Inc.). On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -68.4%). Intellia Therapeutics, Inc. produced more free cash flow last quarter ($-69.4M vs $-74.5M). Over the past eight quarters, Intellia Therapeutics, Inc.'s revenue compounded faster (-10.8% CAGR vs -56.5%).
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
ARCT vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.2M | $23.0M |
| Net Profit | — | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | — | -428.9% |
| Net Margin | — | -416.2% |
| Revenue YoY | -68.4% | 78.8% |
| Net Profit YoY | 3.1% | 25.7% |
| EPS (diluted) | — | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.2M | $23.0M | ||
| Q3 25 | $17.2M | $13.8M | ||
| Q2 25 | $28.3M | $14.2M | ||
| Q1 25 | $29.4M | $16.6M | ||
| Q4 24 | $22.8M | $12.9M | ||
| Q3 24 | $41.7M | $9.1M | ||
| Q2 24 | $49.9M | $7.0M | ||
| Q1 24 | $38.0M | $28.9M |
| Q4 25 | — | $-95.8M | ||
| Q3 25 | $-13.4M | $-101.3M | ||
| Q2 25 | $-9.2M | $-101.3M | ||
| Q1 25 | $-14.1M | $-114.3M | ||
| Q4 24 | $-30.0M | $-128.9M | ||
| Q3 24 | $-6.9M | $-135.7M | ||
| Q2 24 | $-17.2M | $-147.0M | ||
| Q1 24 | $-26.8M | $-107.4M |
| Q4 25 | — | -428.9% | ||
| Q3 25 | -96.3% | -808.9% | ||
| Q2 25 | -41.0% | -772.2% | ||
| Q1 25 | -57.3% | -726.6% | ||
| Q4 24 | -146.7% | -1059.9% | ||
| Q3 24 | -25.8% | -1589.0% | ||
| Q2 24 | -42.4% | -1998.6% | ||
| Q1 24 | -80.0% | -394.0% |
| Q4 25 | — | -416.2% | ||
| Q3 25 | -78.4% | -735.2% | ||
| Q2 25 | -32.4% | -710.8% | ||
| Q1 25 | -47.9% | -687.6% | ||
| Q4 24 | -131.8% | -1001.2% | ||
| Q3 24 | -16.6% | -1489.5% | ||
| Q2 24 | -34.5% | -2112.6% | ||
| Q1 24 | -70.5% | -371.3% |
| Q4 25 | — | $-0.81 | ||
| Q3 25 | $-0.49 | $-0.92 | ||
| Q2 25 | $-0.34 | $-0.98 | ||
| Q1 25 | $-0.52 | $-1.10 | ||
| Q4 24 | $-1.10 | $-1.27 | ||
| Q3 24 | $-0.26 | $-1.34 | ||
| Q2 24 | $-0.64 | $-1.52 | ||
| Q1 24 | $-1.00 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $230.9M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $214.0M | $671.4M |
| Total Assets | $271.1M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.9M | $449.9M | ||
| Q3 25 | $180.4M | $511.0M | ||
| Q2 25 | $196.5M | $459.7M | ||
| Q1 25 | $216.9M | $503.7M | ||
| Q4 24 | $237.0M | $601.5M | ||
| Q3 24 | $237.2M | $658.1M | ||
| Q2 24 | $260.3M | $691.1M | ||
| Q1 24 | $288.4M | $791.3M |
| Q4 25 | $214.0M | $671.4M | ||
| Q3 25 | $224.6M | $748.4M | ||
| Q2 25 | $231.1M | $715.3M | ||
| Q1 25 | $233.8M | $779.9M | ||
| Q4 24 | $241.0M | $872.0M | ||
| Q3 24 | $261.9M | $962.6M | ||
| Q2 24 | $258.6M | $971.1M | ||
| Q1 24 | $264.0M | $1.0B |
| Q4 25 | $271.1M | $842.1M | ||
| Q3 25 | $282.3M | $925.3M | ||
| Q2 25 | $309.3M | $898.9M | ||
| Q1 25 | $331.8M | $986.2M | ||
| Q4 24 | $344.1M | $1.2B | ||
| Q3 24 | $370.7M | $1.2B | ||
| Q2 24 | $388.6M | $1.2B | ||
| Q1 24 | $418.8M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-74.3M | $-69.3M |
| Free Cash FlowOCF − Capex | $-74.5M | $-69.4M |
| FCF MarginFCF / Revenue | -1035.2% | -301.6% |
| Capex IntensityCapex / Revenue | 3.2% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-74.3M | $-69.3M | ||
| Q3 25 | $-17.2M | $-76.9M | ||
| Q2 25 | $-5.8M | $-99.6M | ||
| Q1 25 | $-35.1M | $-148.9M | ||
| Q4 24 | $-284.0K | $-85.2M | ||
| Q3 24 | $-23.8M | $-84.8M | ||
| Q2 24 | $-30.1M | $-58.2M | ||
| Q1 24 | $-5.6M | $-120.7M |
| Q4 25 | $-74.5M | $-69.4M | ||
| Q3 25 | $-17.3M | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | $-35.3M | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | $-23.8M | $-86.1M | ||
| Q2 24 | $-30.5M | $-59.2M | ||
| Q1 24 | $-5.8M | $-123.2M |
| Q4 25 | -1035.2% | -301.6% | ||
| Q3 25 | -101.1% | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | -120.1% | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | -57.2% | -945.2% | ||
| Q2 24 | -61.1% | -850.9% | ||
| Q1 24 | -15.3% | -425.7% |
| Q4 25 | 3.2% | 0.5% | ||
| Q3 25 | 1.1% | 0.2% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.5% | 4.4% | ||
| Q4 24 | 0.0% | 7.6% | ||
| Q3 24 | 0.2% | 14.0% | ||
| Q2 24 | 0.7% | 14.5% | ||
| Q1 24 | 0.6% | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARCT
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
